Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

IF 3 Q2 ONCOLOGY
Sarah J. Wu MD, PhD , Justin J. Kim GED , Yeying Huang BS , R. Taylor Durall BS , Simone Becker RN , Stephanie Canty CNP, MSN , Stefania Molinaro BS , Evan Pisick MD , Geoffrey I. Shapiro MD, PhD , Christopher A. French MD , Jia Luo MD
{"title":"Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report","authors":"Sarah J. Wu MD, PhD ,&nbsp;Justin J. Kim GED ,&nbsp;Yeying Huang BS ,&nbsp;R. Taylor Durall BS ,&nbsp;Simone Becker RN ,&nbsp;Stephanie Canty CNP, MSN ,&nbsp;Stefania Molinaro BS ,&nbsp;Evan Pisick MD ,&nbsp;Geoffrey I. Shapiro MD, PhD ,&nbsp;Christopher A. French MD ,&nbsp;Jia Luo MD","doi":"10.1016/j.jtocrr.2023.100625","DOIUrl":null,"url":null,"abstract":"<div><p>We present the first known case of a patient with <em>BRD2::NUTM1</em>-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a <em>BRD2::NUTM1</em> fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001686/pdfft?md5=5196d7d17fc051b503b55fe9e7f25b4e&pid=1-s2.0-S2666364323001686-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001686","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We present the first known case of a patient with BRD2::NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2::NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.

NUT癌中的新型BRD2::NUTM1融合,对化疗反应特殊:病例报告
我们介绍了第一例已知的BRD2::NUTM1驱动的NUT癌患者。一名 59 岁的女性患者因分化不良的鳞状细胞肺癌转移至胸膜而就诊。最终,经NUT免疫组化阳性、NUT荧光原位杂交和BRD2::NUTM1融合的RNA新一代测序,确诊为NUT癌。她接受了多线化疗,但均有反应,确诊后两年仍健在。本报告扩展了已知的 NUT 癌融合基因,并强调了根据基因融合伙伴的不同,患者预后可能存在的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信